111 related articles for article (PubMed ID: 12656710)
1. Nalpha-methylhistamine safety and efficacy in migraine prophylaxis: phase I and phase II studies.
Millán-Guerrero RO; Pineda-Lucatero AG; Hernández-Benjamín T; Tene CE; Pacheco MF
Headache; 2003 Apr; 43(4):389-94. PubMed ID: 12656710
[TBL] [Abstract][Full Text] [Related]
2. Nalpha-methyl histamine safety and efficacy in migraine prophylaxis: phase III study.
Millán-Guerrero RO; Isais-Millán R; Benjamín TH; Tene CE
Can J Neurol Sci; 2006 May; 33(2):195-9. PubMed ID: 16736729
[TBL] [Abstract][Full Text] [Related]
3. N alpha methyl histamine versus propranolol in migraine prophylaxis.
Millán-Guerrero RO; Isais-Millán R; Guzmán-Chávez B; Castillo-Varela G
Can J Neurol Sci; 2014 Mar; 41(2):233-8. PubMed ID: 24534036
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study.
Millán-Guerrero RO; Isais-Millán R; Barreto-Vizcaíno S; Gutiérrez I; Rivera-Castaño L; Trujillo-Hernández B; Baltazar LM
Eur Neurol; 2008; 59(5):237-42. PubMed ID: 18264012
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study.
Millán-Guerrero RO; Isais-Millán S; Barreto-Vizcaíno S; Rivera-Castaño L; Rios-Madariaga C
Eur J Neurol; 2009 Jan; 16(1):88-94. PubMed ID: 19087155
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, double-blind study.
Millán-Guerrero RO; Isais-Millán R; Barreto-Vizcaíno S; Rivera-Castaño L; Garcia-Solorzano A; López-Blanca C; Membrila-Maldonado M; Muñoz-Solis R
Eur J Neurol; 2007 Oct; 14(10):1079-84. PubMed ID: 17880560
[TBL] [Abstract][Full Text] [Related]
7. [New therapeutic alternatives in migraine prophylaxis using histamine H3 receptor agonists].
Millán-Guerrero RO; Isais-Millán R
Gac Med Mex; 2008; 144(4):291-5. PubMed ID: 18942262
[TBL] [Abstract][Full Text] [Related]
8. [Subcutaneous histamine in migraine prophylaxis. Initial effects and long-term outcome].
Millán Guerrero R; Trujillo Hernández B; Tene CE
Neurologia; 2006 Mar; 21(2):55-9. PubMed ID: 16525910
[TBL] [Abstract][Full Text] [Related]
9. Histamine as a therapeutic alternative in migraine prophylaxis: a randomized, placebo-controlled, double-blind study.
Guerrero RO; Cárdenas MA; Ocampo AA; Pacheco MF
Headache; 1999 Sep; 39(8):576-80. PubMed ID: 11279974
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of R-alpha-methylhistamine, a selective histamine H3 receptor agonist, in rats: lack of involvement of histamine H3 receptors.
Hegde SS; Chan P; Eglen RM
Eur J Pharmacol; 1994 Jan; 251(1):43-51. PubMed ID: 7907986
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of sympathetic hypertensive responses in the guinea-pig by prejunctional histamine H3-receptors.
Hey JA; del Prado M; Egan RW; Kreutner W; Chapman RW
Br J Pharmacol; 1992 Oct; 107(2):347-51. PubMed ID: 1330174
[TBL] [Abstract][Full Text] [Related]
12. Characterization of histamine-H3 receptors controlling non-adrenergic non-cholinergic contractions of the guinea-pig isolated ileum.
Taylor SJ; Kilpatrick GJ
Br J Pharmacol; 1992 Mar; 105(3):667-74. PubMed ID: 1352720
[TBL] [Abstract][Full Text] [Related]
13. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
Lim HD; van Rijn RM; Ling P; Bakker RA; Thurmond RL; Leurs R
J Pharmacol Exp Ther; 2005 Sep; 314(3):1310-21. PubMed ID: 15947036
[TBL] [Abstract][Full Text] [Related]
15. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
16. Production by R-alpha-methylhistamine of a histamine H3 receptor-mediated decrease in basal vascular resistance in guinea-pigs.
McLeod RL; Gertner SB; Hey JA
Br J Pharmacol; 1993 Oct; 110(2):553-8. PubMed ID: 7902173
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study.
Pfaffenrath V; Diener HC; Fischer M; Friede M; Henneicke-von Zepelin HH;
Cephalalgia; 2002 Sep; 22(7):523-32. PubMed ID: 12230594
[TBL] [Abstract][Full Text] [Related]
18. Histamine H3 receptor activation potentiates peripheral opioid-mediated antinociception: substance P role in peripheral inflammation in mice.
Fernández-Dueñas V; Ciruela F; Gandía J; Sánchez S; Planas E; Poveda R
Eur J Pharmacol; 2010 Jul; 638(1-3):72-7. PubMed ID: 20435034
[TBL] [Abstract][Full Text] [Related]
19. Effects of histamine H3 receptor ligands in experimental models of anxiety and depression.
Pérez-García C; Morales L; Cano MV; Sancho I; Alguacil LF
Psychopharmacology (Berl); 1999 Feb; 142(2):215-20. PubMed ID: 10102775
[TBL] [Abstract][Full Text] [Related]
20. Azomethine prodrugs of (R)-alpha-methylhistamine, a highly potent and selective histamine H3-receptor agonist.
Krause M; Stark H; Schunack W
Curr Med Chem; 2001 Sep; 8(11):1329-40. PubMed ID: 11562269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
